We evaluated the associations of plasma levels with AD pathologies as measured with CSF Aβ42, Aβ42/Aβ40, p-tau181, t-tau, p-tau/Aβ42, t-tau/Aβ42, NfL (Fig. 3A), and Aβ PET (Fig. 3B). This evidence concerns the gene MAPT and Alzheimer disease.